File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Magnetic resonance imaging-ultrasound fusion prostate biopsy – a new era of prostate cancer diagnosis

TitleMagnetic resonance imaging-ultrasound fusion prostate biopsy – a new era of prostate cancer diagnosis
Authors
Issue Date2019
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/
Citation
The 23rd Hong Kong Urological Assoication Annual Scientific Meeting, Hong Kong, 4 November 2018. In BJU International, v. 123 n. S1, p. 6 How to Cite?
AbstractObjective: MRI‐TRUS fusion targeted biopsy (TB) has been available in our centre since 2015. We herein compare MRI‐TRUS fusion prostate biopsy with standard 12‐core systematic biopsy (SB). Patients and Methods: Data of Chinese patients undergone prostate biopsy in Queen Mary Hospital from July 2015 to April 2018 were prospectively collected. We investigate the overall and csPCa detection rate of TB + SB and SB. Results: 382 patients were included in our study. Multi‐parametric MRI (mpMRI) had NPV 100% for patients with PI‐RADS score ≤ 2. The overall cancer detection rate of TB + SB for first‐time biopsy in patients with PI‐RADS 3–5 lesions was 47.4%, significantly higher than 31.8% in SB (p = 0.006). Significance was also observed in repeat biopsy setting (24.7% vs 14.7%, p = 0.047). TB alone would have detected 41.6% less clinically insignificant PCa and missed 13.6% of csPCa. The receiver operating characteristic (ROC) curve analysis showed that adding mpMRI PI‐RADS grading to other clinical predictors had an area under curve (AUC) of 0.87 (95% CI 0.82–0.92) for prediction of any grade and csPCa. Conclusions: MRI‐US fusion biopsy is a promising modality in prostate cancer diagnosis and will benefit patients in both first‐time and repeat biopsy setting.
DescriptionOral presentation
Persistent Identifierhttp://hdl.handle.net/10722/266488
ISSN
2017 Impact Factor: 4.688
2015 SCImago Journal Rankings: 2.009

 

DC FieldValueLanguage
dc.contributor.authorLai, TCT-
dc.contributor.authorMa, WK-
dc.contributor.authorLam, AKC-
dc.contributor.authorLam, ACS-
dc.contributor.authorTsang, CF-
dc.contributor.authorLam, PW-
dc.contributor.authorHo, SHB-
dc.contributor.authorNg, ATL-
dc.contributor.authorTsu, HLJ-
dc.date.accessioned2019-01-18T08:20:37Z-
dc.date.available2019-01-18T08:20:37Z-
dc.date.issued2019-
dc.identifier.citationThe 23rd Hong Kong Urological Assoication Annual Scientific Meeting, Hong Kong, 4 November 2018. In BJU International, v. 123 n. S1, p. 6-
dc.identifier.issn1464-4096-
dc.identifier.urihttp://hdl.handle.net/10722/266488-
dc.descriptionOral presentation-
dc.description.abstractObjective: MRI‐TRUS fusion targeted biopsy (TB) has been available in our centre since 2015. We herein compare MRI‐TRUS fusion prostate biopsy with standard 12‐core systematic biopsy (SB). Patients and Methods: Data of Chinese patients undergone prostate biopsy in Queen Mary Hospital from July 2015 to April 2018 were prospectively collected. We investigate the overall and csPCa detection rate of TB + SB and SB. Results: 382 patients were included in our study. Multi‐parametric MRI (mpMRI) had NPV 100% for patients with PI‐RADS score ≤ 2. The overall cancer detection rate of TB + SB for first‐time biopsy in patients with PI‐RADS 3–5 lesions was 47.4%, significantly higher than 31.8% in SB (p = 0.006). Significance was also observed in repeat biopsy setting (24.7% vs 14.7%, p = 0.047). TB alone would have detected 41.6% less clinically insignificant PCa and missed 13.6% of csPCa. The receiver operating characteristic (ROC) curve analysis showed that adding mpMRI PI‐RADS grading to other clinical predictors had an area under curve (AUC) of 0.87 (95% CI 0.82–0.92) for prediction of any grade and csPCa. Conclusions: MRI‐US fusion biopsy is a promising modality in prostate cancer diagnosis and will benefit patients in both first‐time and repeat biopsy setting.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/-
dc.relation.ispartofBJU International-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.titleMagnetic resonance imaging-ultrasound fusion prostate biopsy – a new era of prostate cancer diagnosis-
dc.typeConference_Paper-
dc.identifier.emailMa, WK: mwk054@hku.hk-
dc.identifier.emailLam, PW: lamwayne@hku.hk-
dc.identifier.emailHo, SHB: hobrian@hku.hk-
dc.identifier.emailNg, ATL: ada5022@hku.hk-
dc.identifier.emailTsu, HLJ: jamestsu@hku.hk-
dc.identifier.authorityLam, PW=rp02305-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/bju.14677-
dc.identifier.hkuros296745-
dc.identifier.volume123-
dc.identifier.issueS1-
dc.identifier.spage6-
dc.identifier.epage6-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats